Bruker–Wells Fargo: investor conference, 202409 supply service Bruker presents at Wells Fargo Healthcare Conference in Boston

	Period	2024-09-04
	Region	Boston, MA
	Country	United States (USA)
	Partner, 1st	Bruker Corporation (Nasdaq: BRKR)
	Group	Bruker (Group)
	Partner, 2nd	Wells Fargo Securities LLC
	Product	Wells Fargo Healthcare Conference 2024 Boston
	Product 2	analytical instrument
	Person	Herman, Gerald N. (Bruker Corp 201806– CFO before Interim CFO joined 12/16 as VP + Corp Controller before Parexel)
	Person 2	Kostka, Joe (Bruker 202408 Associate Director Invesor Relations)

Bruker Corporation. (8/23/24). "Press Release: Bruker Corporation to Present at Upcoming Investor Conferences". Billerica, MA.

Bruker Corporation (Nasdaq: BRKR) announced today that Gerald Herman, Executive Vice President & CFO will present on behalf of the Company at the following investor conferences:

2024 Wells Fargo Healthcare Conference in Boston, MA
Wednesday, September 4, 2024, at 10:15 a.m. Eastern Time

Morgan Stanley 22nd Annual Global Healthcare Conference in New York City
Friday, September 6, 2024, at 10:00 a.m. Eastern Time

Live audiovisual webcasts of the presentations will be available on the Investor Relations section of the Company's website at https://ir.bruker.com . Replays of the presentations will be posted in the “Events & Presentations” section of the Bruker Corporation Investor Relations website after the events and will be available for 90 days following the presentations.

About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)

Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com .

Joe Kostka
Associate Director, Investor Relations
Bruker Corporation
T: +1 (978) 313-5800
E: Investor.Relations@bruker.com